MIT Spinout Develops Adhesive for Surgical Tissue Closure

SanaHeal, an MIT spinout, has developed a bioadhesive that sticks to wet, uneven tissue and forms air- and fluid-tight seals, aiming to simplify surgical tissue connection. According to MIT News, the product has regulatory approval for trauma bleeding control, while surgical bleeding and tissue-repair human trials are planned for next year. The company targets procedures now performed with sutures or staples. MIT News report.

Technology and design

SanaHeal describes its product as a biologically compatible adhesive made from polymers and water. It is designed to absorb water from wet tissue and adhere rapidly, drawing inspiration from sticky materials such as barnacles and spider webs. Early versions acted like double-sided tape, using polyacrylic acid to absorb water from tissue surfaces.

The materials are described as minimizing immune responses and scar tissue buildup compared with sutures and staples, which the source says can damage tissue and trigger complications. The technology is intended to create air- and fluid-tight seals on uneven surfaces in surgical settings. Its stated aim is less invasive tissue connection, including use with surgical robots.

Related coverage: related Health Tech reporting.

Clinical scope and status

MIT News reports that the SanaHeal technology has gained regulatory approval to stop trauma bleeding. That clearance does not establish approval for surgical bleeding control or tissue repair. Next year, the company plans human trials for controlling bleeding during surgeries and repairing injured tissues. Those applications remain planned, not completed.

The source frames surgical applications as a major unmet need across open, laparoscopic and endoscopic procedures. SanaHeal says its technology can be combined with existing devices for sutureless implantation in uses such as hernia and nerve repair. It also cites use in microsurgery, where tiny tissues can require very thin needles.

Related coverage: related Health Tech reporting.

Partnership model

SanaHeal presents itself as a platform company that supplies its adhesive technology to larger medical device partners. The founder says the startup lacks resources to develop many products at once, so partners take on clinical trials and commercialization. Partners are described as developing products for open, laparoscopic and endoscopic surgeries.

The company states its technology can work with existing devices and in sutureless implantation, indicating a component role rather than a finished product. MIT News attributes the partner-development scope to SanaHeal.

Related coverage: related Health Tech reporting.

Origins and funding

The technology originated in the MIT lab of Xuanhe Zhao, professor of mechanical engineering, where founder and chief technology officer Hyunwoo Yuk studied hydrogels. SanaHeal was officially formed in 2021. The founders received funding from the MIT Deshpande Center to begin development. Yuk used MIT Venture Mentoring Service and the Technology Licensing Office while exploring interest.

Yuk says the team initially focused on wounds to stop bleeding before shifting toward surgical applications, which the company viewed as more numerous. He says regulatory hurdles made early partnering too risky, prompting the founders to commercialize the technology themselves. Yuk says commercialization has taken longer than he expected.

Related coverage: related Health Tech reporting.

What This Means for Practitioners

Editorial assessment. Buyers and research partners should ask whether the trauma-bleeding approval covers the specific surgical uses under discussion, and whether planned human trials will test the exact tissue types and procedures described. They should request trial designs, endpoints and safety monitoring plans before treating the adhesive as a validated alternative to sutures or staples.

They should also ask which partners are developing products, what clinical evidence each partner has generated, and how compatibility with surgical robots and existing devices is being assessed. Our recommendation is to make any interest conditional on disclosed trial scope, regulatory pathway and independent evidence beyond vendor descriptions.